Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 3Thoracic 2Sarcoma 2Plasma cell 2Lymphoid 2Other hematologic neoplasm 1Classical hematology 1

Conditions

Lymphoma 201Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Lymphoma, Non-Hodgkin 112Lymphoma, Large B-Cell, Diffuse 108Leukemia 106Lymphoma, Follicular 93Hodgkin Disease 92Burkitt Lymphoma 91Lymphoma, Mantle-Cell 87Leukemia, Lymphocytic, Chronic, B-Cell 84Lymphoma, Large-Cell, Immunoblastic 73Myelodysplastic Syndromes 63Leukemia, Myeloid, Acute 61Lymphoma, B-Cell, Marginal Zone 59Multiple Myeloma 48Dendritic Cell Sarcoma, Interdigitating 38Recurrence 33Leukemia, Myeloid, Chronic-Phase 33Myeloproliferative Disorders 32Leukemia, Myeloid, Accelerated Phase 32Neoplasms, Plasma Cell 28Blast Crisis 27Leukemia, Myelomonocytic, Chronic 25Lymphoma, Large-Cell, Anaplastic 22Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 21Waldenstrom Macroglobulinemia 20Myelodysplastic-Myeloproliferative Diseases 20Congenital Abnormalities 20Lymphoma, T-Cell, Cutaneous 19Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 19

Interventions

Cyclophosphamide 5Etoposide 4Cytarabine 3sargramostim 2denileukin diftitox 2Radiotherapy 2Filgrastim 2Dexamethasone 2Carboplatin 2Amifostine 2sodium thiosulfate 1pegfilgrastim 1pegaspargase 1glucarpidase 1etoposide phosphate 1Vincristine 1Silymarin 1Rituximab 1Prednisolone 1Phenobarbital 1Methylprednisolone 1Methotrexate 1Mercaptopurine 1Leucovorin 1Irinotecan 1Ifosfamide 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Fibroblast Growth Factor 7 1Epoetin Alfa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Filgrastim × Lymphoid × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

NCT00004132 2013-06-26

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
LymphoidOther hematologic neoplasmPlasma cellSarcoma

Blast Crisis, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Radiation Injuries, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡